{"id":545753,"date":"2021-06-01T20:58:01","date_gmt":"2021-06-01T20:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545753"},"modified":"2021-06-01T20:58:01","modified_gmt":"2021-06-01T20:58:01","slug":"netherton-syndrome-ns-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/netherton-syndrome-ns-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_545753.html","title":{"rendered":"Netherton Syndrome (NS) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Netherton<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cNetherton Syndrome (NS)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Netherton Syndrome (NS), historical and forecasted epidemiology as well as the Netherton Syndrome (NS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Netherton Syndrome (NS)-Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Netherton Syndrome (NS)–Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Netherton Syndrome (NS), historical and forecasted epidemiology as well as the Netherton Syndrome (NS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

 <\/p>\n

    \n
  1. \n

    According to an article published in Orphanet Journal of Rare Diseases, prevalence of Syndromic Ichthyosis was estimated at 1.9 per million (95% CI [1.6–2.6]). Netherton Syndrome was the most frequent form, with 0.80 per million (95% CI [0.66–1.06]).<\/p>\n<\/li>\n

  2. \n

    According to the research, Netherton syndrome is a rare hereditary disorder. There are approximately 150 cases reported in the medical literature, but the true number of affected individuals may be much higher due to diagnostic difficulties and overlapping symptoms with common atopic dermatitis and other Congenital Ichthyoses.<\/p>\n<\/li>\n

  3. \n

    According to an Association, Netherton syndrome is rare with its prevalence being higher in females. In Japan, more than 10 patients have been reported. The prevalence is reportedly approximately 1 per 200,000 neonates.<\/p>\n<\/li>\n

  4. \n

    According to the Genetics Home Reference, Netherton syndrome is estimated to affect 1 in 200,000 newborns.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Netherton Syndrome (NS) market report covers a descriptive overview and comprehensive insight of the Netherton Syndrome (NS) epidemiology and Netherton Syndrome (NS) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Netherton Syndrome (NS) market report provides insights into the current and emerging therapies.<\/p>\n

    3.Netherton Syndrome (NS) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Netherton Syndrome (NS) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Netherton Syndrome (NS) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Netherton Syndrome (NS): Overview<\/strong><\/p>\n

    Netherton syndrome is a disorder that affects the skin, hair, and immune system. Newborns with Netherton syndrome have skin that is red and scaly (ichthyosiform erythroderma), and the skin may leak fluid. Some affected infants are born with a tight, clear sheath covering their skin called a collodion membrane. This membrane is usually shed during the first few weeks of life. Because newborns with this disorder are missing the protection provided by normal skin, they are at risk of becoming dehydrated and developing infections in the skin or throughout the body (sepsis), which can be life-threatening. Affected babies may also fail to grow and gain weight at the expected rate (failure to thrive). The health of older children and adults with Netherton syndrome usually improves, although they often remain underweight and of short stature.<\/p>\n

    The key players involved in the Netherton Syndrome (NS) market<\/a>:<\/strong><\/p>\n

     <\/p>\n

      \n
    1. \n

      LifeMax Laboratories <\/p>\n<\/li>\n

    2. \n

      Dermelix Biotherapeutics<\/p>\n<\/li>\n

    3. \n

      BridgeBio Pharma <\/p>\n<\/li>\n

    4. \n

      Sixera Pharma<\/p>\n<\/li>\n

    5. \n

      Quoin Pharma<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Netherton Syndrome (NS) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        LM-030<\/p>\n<\/li>\n

      2. \n

        DMX-102<\/p>\n<\/li>\n

      3. \n

        BBP-561<\/p>\n<\/li>\n

      4. \n

        SXR1096<\/p>\n<\/li>\n

      5. \n

        QRX003<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/netherton-syndrome-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Netherton Syndrome (NS) Patient Share (%) Overview at a Glance<\/p>\n

        5. Netherton Syndrome (NS) Market Overview at a Glance<\/p>\n

        6. Netherton Syndrome (NS) Disease Background and Overview<\/p>\n

        7. Netherton Syndrome (NS) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Netherton Syndrome (NS) <\/p>\n

        9. Netherton Syndrome (NS) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Netherton Syndrome (NS) Emerging Therapies<\/p>\n

        12. Netherton Syndrome (NS) Market Outlook<\/p>\n

        13. Country-Wise Netherton Syndrome (NS) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Netherton Syndrome (NS) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Netherton Syndrome (NS)-Pipeline Insights, 2021<\/strong><\/p>\n

        “Netherton Syndrome (NS)-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Netherton Syndrome (NS) market. A detailed picture of the Netherton Syndrome (NS) pipeline landscape is provided, which includes the disease overview and Netherton Syndrome (NS) treatment guidelines.<\/p>\n

        Netherton Syndrome (NS)-Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Netherton Syndrome (NS)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Netherton Syndrome (NS){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cNetherton Syndrome (NS)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Netherton Syndrome (NS), historical and forecasted epidemiology as well as the Netherton Syndrome (NS) market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545753","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545753"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}